Impact of reducing the duration of antibiotic treatment on the long-term prognosis of community acquired pneumonia

Uranga, Ane; Artaraz, Amaia; Bilbao, Amaia; Quintana, José M.; Arriaga, Ignacio; Intxausti, Maider; Lobo, José Luís; García, Julia A.; Camino, Jesús; España, Pedro Pablo

doi:10.1186/s12890-020-01293-6

Cited by 4 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior data suggest that excessive antibiotic use does not improve patient outcomes [ 60 ]. To ensure no unintended patient harm occurs from reducing antibiotic overuse at discharge, we will use a non-inferiority framework to analyze composite 30-day post-discharge patient outcomes including mortality, readmission, or urgent visit (i.e., urgent care or emergency care visit).…”

Section: Methods and Analysismentioning

confidence: 99%

Protocol for a parallel cluster randomized trial of a participatory tailored approach to reduce overuse of antibiotics at hospital discharge: the ROAD home trial

Szymczak,

Petty,

Gandhi

et al. 2024

Implementation Sci

View full text Add to dashboard Cite

Background Antibiotic overuse at hospital discharge is common, costly, and harmful. While discharge-specific antibiotic stewardship interventions are effective, they are resource-intensive and often infeasible for hospitals with resource constraints. This weakness impacts generalizability of stewardship interventions and has health equity implications as not all patients have access to the benefits of stewardship based on where they receive care. There may be different pathways to improve discharge antibiotic prescribing that vary widely in feasibility. Supporting hospitals in selecting interventions tailored to their context may be an effective approach to feasibly reduce antibiotic overuse at discharge across diverse hospitals. The objective of this study is to evaluate the effectiveness of the Reducing Overuse of Antibiotics at Discharge Home multicomponent implementation strategy (“ROAD Home”) on antibiotic overuse at discharge for community-acquired pneumonia and urinary tract infection. Methods This 4-year two-arm parallel cluster-randomized trial will include three phases: baseline (23 months), intervention (12 months), and postintervention (12 months). Forty hospitals recruited from the Michigan Hospital Medicine Safety Consortium will undergo covariate-constrained randomization with half randomized to the ROAD Home implementation strategy and half to a “stewardship as usual” control. ROAD Home is informed by the integrated-Promoting Action on Research Implementation in Health Services Framework and includes (1) a baseline needs assessment to create a tailored suite of potential stewardship interventions, (2) supported decision-making in selecting interventions to implement, and (3) external facilitation following an implementation blueprint. The primary outcome is baseline-adjusted days of antibiotic overuse at discharge. Secondary outcomes include 30-day patient outcomes and antibiotic-associated adverse events. A mixed-methods concurrent process evaluation will identify contextual factors influencing the implementation of tailored interventions, and assess implementation outcomes including acceptability, feasibility, fidelity, and sustainment. Discussion Reducing antibiotic overuse at discharge across hospitals with varied resources requires tailoring of interventions. This trial will assess whether a multicomponent implementation strategy that supports hospitals in selecting evidence-based stewardship interventions tailored to local context leads to reduced overuse of antibiotics at discharge. Knowledge gained during this study could inform future efforts to implement stewardship in diverse hospitals and promote equity in access to the benefits of quality improvement initiatives. Trial registration Clinicaltrials.gov NCT06106204 on 10/30/23

show abstract

Section: Methods and Analysismentioning

confidence: 99%

Protocol for a parallel cluster randomized trial of a participatory tailored approach to reduce overuse of antibiotics at hospital discharge: the ROAD home trial

Szymczak,

Petty,

Gandhi

et al. 2024

Implementation Sci

View full text Add to dashboard Cite

show abstract

“…Recently, there has been a growing number of studies shifting the paradigm to use shorter antibiotic courses in infections such as osteomyelitis, pneumonia, and UTI in women. 19,[68][69][70] However, the optimal duration of therapy for men with presumed UTI has not been clearly defined.…”

Section: Drekonja Et Al Effect Of 7 Vs 14 Days Of Antibiotic Therapy ...mentioning

confidence: 99%

Significant Publications on Infectious Diseases Pharmacotherapy in 2021

Nguyen

Chua

Drake

et al. 2022

Journal of Pharmacy Practice

View full text Add to dashboard Cite

Purpose: To summarize the most noteworthy infectious diseases (ID) pharmacotherapy articles published in peer-reviewed literature in 2021. Summary: Members of the Houston Infectious Diseases Network (HIDN) nominated articles that were deemed to have significant contributions to ID pharmacotherapy in 2021. These nominations included articles pertaining to both general ID, including coronavirus disease 2019 (COVID-19), and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pharmacotherapy. A total of 35 articles were nominated by HIDN: 30 articles pertaining to general ID pharmacotherapy and 5 articles with HIV/AIDS focus. To select the most influential articles of 2021, a survey was created and distributed to members of the Society of Infectious Diseases Pharmacists (SIDP). Of the 239 SIDP members who responded to the survey, there were 192 recorded votes for the top 10 general ID pharmacotherapy articles and 47 recorded votes for the top HIV/AIDS article, respectively. The top publications are summarized. Conclusion: Antimicrobial stewardship and the optimal management of infectious disease states continues to be a priority in the midst of the ongoing coronavirus disease 2019 (COVID-19) global pandemic. In light of the sheer volume of ID-related articles published in the past year, this review aims to aid clinicians in remaining up-to-date on key practice-changing ID pharmacotherapy publications from 2021.

show abstract

Correction to: Impact of reducing the duration of antibiotic treatment on the long-term prognosis of community acquired pneumonia

et al. 2021

View full text Add to dashboard Cite

show abstract

Impact of reducing the duration of antibiotic treatment on the long-term prognosis of community acquired pneumonia

Cited by 4 publications

References 37 publications

Protocol for a parallel cluster randomized trial of a participatory tailored approach to reduce overuse of antibiotics at hospital discharge: the ROAD home trial

Protocol for a parallel cluster randomized trial of a participatory tailored approach to reduce overuse of antibiotics at hospital discharge: the ROAD home trial

Significant Publications on Infectious Diseases Pharmacotherapy in 2021

Correction to: Impact of reducing the duration of antibiotic treatment on the long-term prognosis of community acquired pneumonia

Contact Info

Product

Resources

About